[
  {
    "ts": null,
    "headline": "Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak",
    "summary": "Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.",
    "url": "https://finnhub.io/api/news?id=d957fc48a5eb959e96b2cb823a54cb45eeb47709d391408d008694ed12aecb7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765560949,
      "headline": "Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak",
      "id": 137769492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.",
      "url": "https://finnhub.io/api/news?id=d957fc48a5eb959e96b2cb823a54cb45eeb47709d391408d008694ed12aecb7b"
    }
  },
  {
    "ts": null,
    "headline": "Kymera's Eczema Drug Gets Fast Track Designation in the United States",
    "summary": "KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.",
    "url": "https://finnhub.io/api/news?id=2a97b5ad59346dc84bf8a0b4c68ac278c9e501edf75acd9a5c9e8d1a3af15b30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553400,
      "headline": "Kymera's Eczema Drug Gets Fast Track Designation in the United States",
      "id": 137769493,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.",
      "url": "https://finnhub.io/api/news?id=2a97b5ad59346dc84bf8a0b4c68ac278c9e501edf75acd9a5c9e8d1a3af15b30"
    }
  },
  {
    "ts": null,
    "headline": "Arcus cancels work on Gilead-partnered cancer combo after trial setback",
    "summary": "A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.",
    "url": "https://finnhub.io/api/news?id=da741d14af00b560af97474af79a8a13fd873c54fe03e30cb4ece5f5cb70734c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765540020,
      "headline": "Arcus cancels work on Gilead-partnered cancer combo after trial setback",
      "id": 137769494,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target.",
      "url": "https://finnhub.io/api/news?id=da741d14af00b560af97474af79a8a13fd873c54fe03e30cb4ece5f5cb70734c"
    }
  }
]